Pancreatic Cancer Research

ResearcherUniversity of California San DiegoActive in the last 2 years

Yukihiko Hiroshima

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0005-7384-3513; OpenAlex author ID A5113917299. Sources: OpenAlex.

Their work

Papers
32 (first author 14, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2013: 4 papers · 2014: 7 papers · 2015: 7 papers · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 32

  1. A Combinatorial Effect of Immune Checkpoint Inhibitors and CD40 Agonistic Antibody in Murine Pancreatic Cancer Model. Co-author DOI 10.1111/cas.70246↗
  2. Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outcomes in Pancreatic Cancer. First author DOI 10.1245/s10434-025-18186-9↗
  3. Neoadjuvant Chemoradiotherapy Enhances Tumor PD-L1 Expression in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17554↗
  4. Evaluation of pancreatic cancer specimens for comprehensive genomic profiling. First author DOI 10.1111/pin.13416↗
  5. CRMP4 Up-regulates M2 Macrophages and Myeloid-derived Suppressor Cells to Promote Pancreatic Cancer in Mice. First author DOI 10.21873/anticanres.15537↗
  6. Reduction of gender-associated M2-like tumor-associated macrophages in the tumor microenvironment of patients with pancreatic cancer after neoadjuvant chemorad… First author DOI 10.1002/jhbp.883↗
  7. Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.canlet.2019.10.031↗
  8. Low Incidence of High-Grade Pancreatic Intraepithelial Neoplasia Lesions in a Crmp4 Gene-Deficient Mouse Model of Pancreatic Cancer. Co-author DOI 10.1016/j.tranon.2020.100746↗
  9. Role of the tumor microenvironment in pancreatic cancer. First author DOI 10.1002/ags3.12225↗
  10. MiR-194-5p in Pancreatic Ductal Adenocarcinoma Peritoneal Washings is Associated with Peritoneal Recurrence and Overall Survival in Peritoneal Cytology-Negativ… First author DOI 10.1245/s10434-019-07793-y↗
  11. Tumor-Targeting Salmonella typhimurium A1-R Promotes Tumoricidal CD8+ T Cell Tumor Infiltration and Arrests Growth and Metastasis in a Syngeneic Pancreatic-Can… First author DOI 10.1002/jcb.26224↗
  12. RT-PCR of peritoneal washings predicts peritoneal pancreatic cancer recurrence. Co-author DOI 10.1016/j.jss.2017.11.009↗
  13. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility co… Co-author DOI 10.1002/jso.24681↗
  14. Color-coded intravital imaging demonstrates a transforming growth factor-β (TGF-β) antagonist selectively targets stromal cells in a human pancreatic-cancer or… First author DOI 10.1080/15384101.2017.1315489↗
  15. Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer. Co-author DOI 10.1002/jso.23816↗
  16. Photoimmunotherapy lowers recurrence after pancreatic cancer surgery in orthotopic nude mouse models. First author DOI 10.1016/j.jss.2015.02.037↗
  17. Fluorescence-guided surgery, but not bright-light surgery, prevents local recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) model r… Co-author DOI 10.1016/j.pan.2015.02.008↗
  18. Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-… First author DOI 10.1038/cgt.2015.26↗
  19. Photoimmunotherapy Inhibits Tumor Recurrence After Surgical Resection on a Pancreatic Cancer Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. Co-author DOI 10.1245/s10434-015-4553-9↗
  20. Near infra-red photoimmunotherapy with anti-CEA-IR700 results in extensive tumor lysis and a significant decrease in tumor burden in orthotopic mouse models of… First author DOI 10.1371/journal.pone.0121989↗
  21. MUC1 selectively targets human pancreatic cancer in orthotopic nude mouse models. First author DOI 10.1371/journal.pone.0122100↗
  22. Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX). Co-author DOI 10.1002/jcb.24769↗
  23. Comparison of UVB and UVC effects on the DNA damage-response protein 53BP1 in human pancreatic cancer. Co-author DOI 10.1002/jcb.24837↗
  24. Specific tumor labeling enhanced by polyethylene glycol linkage of near infrared dyes conjugated to a chimeric anti-carcinoembryonic antigen antibody in a nude… First author DOI 10.1117/1.jbo.19.10.101504↗
  25. Fluorescence-guided surgery in combination with UVC irradiation cures metastatic human pancreatic cancer in orthotopic mouse models. Co-author DOI 10.1371/journal.pone.0099977↗
  26. The tumor-educated-macrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic acid. Co-author DOI 10.1371/journal.pone.0103382↗
  27. Metastatic recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) nude mouse model is inhibited by neoadjuvant chemotherapy in combinati… Co-author DOI 10.1371/journal.pone.0114310↗
  28. Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenogra… Co-author DOI 10.18632/oncotarget.2641↗
  29. Comparison of a chimeric anti-carcinoembryonic antigen antibody conjugated with visible or near-infrared fluorescent dyes for imaging pancreatic cancer in orth… First author DOI 10.1117/1.jbo.18.12.126016↗
  30. Collapsin response mediator protein 4 expression is associated with liver metastasis and poor survival in pancreatic cancer. Co-author DOI 10.1245/s10434-012-2491-3↗
  31. Comparison of efficacy of Salmonella typhimurium A1-R and chemotherapy on stem-like and non-stem human pancreatic cancer cells. Co-author DOI 10.4161/cc.25872↗
  32. Single cell time-lapse imaging of focus formation by the DNA damage-response protein 53BP1 after UVC irradiation of human pancreatic cancer cells. Co-author PMID 23564775↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Itaru Endo · 22 shared papers, 2013–2026 · strength 1.84
  2. Robert M. Hoffman · 24 shared papers, 2013–2025 · strength 1.39
  3. Michael Bouvet · 22 shared papers, 2013–2020 · strength 1.08
  4. Takashi Murakami · 12 shared papers, 2014–2025 · strength 0.94
  5. Ali A. Maawy · 15 shared papers, 2013–2015 · strength 0.64
  6. Yuki Homma · 6 shared papers, 2017–2022 · strength 0.61
  7. Yasuhiro Yabushita · 4 shared papers, 2019–2025 · strength 0.59
  8. Kentaro Miyake · 5 shared papers, 2017–2025 · strength 0.56
  9. Yohei Miyagi · 3 shared papers, 2020–2025 · strength 0.49
  10. Naoto Yamamoto · 3 shared papers, 2020–2025 · strength 0.49
  11. Yasushi Ichikawa · 8 shared papers, 2013–2020 · strength 0.40
  12. Kota Washimi · 2 shared papers, 2024–2025 · strength 0.39
  13. Satoshi Kobayashi · 2 shared papers, 2024–2025 · strength 0.39
  14. Makoto Ueno · 2 shared papers, 2024–2025 · strength 0.39
  15. Tomohiko Tamura · 2 shared papers, 2021–2026 · strength 0.39
  16. Kanechika Den · 2 shared papers, 2017–2025 · strength 0.30
  17. Soichiro Morinaga · 2 shared papers, 2020–2025 · strength 0.29
  18. Shingo Kato · 2 shared papers, 2013–2026 · strength 0.29
  19. Shuya Yano · 8 shared papers, 2013–2015 · strength 0.28
  20. Juri Ichikawa · 1 shared paper, 2026 · strength 0.26
  21. Shin Maeda · 1 shared paper, 2026 · strength 0.26
  22. Keiichi Yazawa · 2 shared papers, 2020–2022 · strength 0.25
  23. Shinji Miwa · 7 shared papers, 2013–2014 · strength 0.24
  24. Fuminari Uehara · 6 shared papers, 2013–2014 · strength 0.21
  25. Yuto Kamioka · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.